Compare ALOT & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALOT | GLTO |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 54.5M |
| IPO Year | N/A | 2020 |
| Metric | ALOT | GLTO |
|---|---|---|
| Price | $9.00 | $26.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 10.8K | ★ 30.0K |
| Earning Date | 12-10-2025 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,340,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.96 | $2.01 |
| 52 Week High | $12.68 | $38.33 |
| Indicator | ALOT | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 56.26 |
| Support Level | $9.10 | $23.85 |
| Resistance Level | $9.50 | $27.75 |
| Average True Range (ATR) | 0.27 | 2.77 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 7.32 | 57.62 |
AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.